Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Director · CHAIRMAN AND CEO | August 25, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date August 25, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 306,461 |
Ending reported balance
After 2026-08-25 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-25 · Exercise / conversion · Acquired 151,869 · Balance 458,330 Row 2 · 2026-08-25 · Exercise / conversion · Acquired 246,963 · Balance 705,293 Row 3 · 2026-08-25 · Sale · Disposed 218,535 · Balance 486,758 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 4 · 2026-08-25 · Sale · Disposed 180,297 · Balance 306,461 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.36, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.40 · Expires 2027-02-16 | Direct | 0 |
Reported balance
After 2026-08-25 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-25 · Exercise / conversion · Disposed 151,869 · Balance 0 F4: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.94 · Expires 2028-02-15 | Direct | 0 |
Reported balance
After 2026-08-25 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-25 · Exercise / conversion · Disposed 246,963 · Balance 0 F5: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectFord Family Trust | 216,203 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 216,203 F3: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.36, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust.
F4: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
F5: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2019 Filed Mar 4, 2019 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 14,682 | $77.23 | $1,133,890.86 |
DisclosureSEC source: 0001179110-19-003114 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,890 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 240,059 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002640 · edgar.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,059 Underlying: Common shares · 240,059 shares Expires 2029-02-21 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 80,019 on February 22, 2020, 80,020 on February 22, 2021, and 80,020 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 45,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002640 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,572 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 299 | $61.53 | $18,397.47 |
DisclosureSEC source: 0001179110-18-008098 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,775 Read SEC document |
| March 06, 2018 Filed Mar 9, 2018 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 15,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-003977 · edgar.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Ford Family Trust Disclosed balance after: 95,492 F1 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| March 06, 2018 Filed Mar 9, 2018 22:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 15,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-003977 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,074 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 10,721 | $60.55 | $649,156.55 |
DisclosureSEC source: 0001179110-18-003302 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,354 Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 246,963 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002535 · edgar.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,963 Underlying: Common shares · 246,963 shares Expires 2028-02-15 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 82,321 on 02/16/2019, 82,321 on 02/16/2020, and 82,321 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 44,909 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002535 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,075 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $63.09 | $37,854.00 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 17 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,166 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $63.09 | $25,234.00 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 16 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,766 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,400 | $63.08 | $151,392.00 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 15 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,166 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $63.08 | $6,307.50 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 14 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,566 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,300 | $63.07 | $81,991.00 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 13 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,666 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,000 | $63.06 | $189,180.00 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 12 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,966 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 202 | $63.06 | $12,737.11 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 11 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,966 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,100 | $63.05 | $132,405.00 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 10 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,168 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $63.05 | $6,304.50 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 9 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,268 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,400 | $63.04 | $151,296.00 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 8 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,368 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $63.04 | $25,214.00 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 7 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,768 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,400 | $63.03 | $88,242.00 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 6 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,168 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 301 | $63.03 | $18,970.53 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 5 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,568 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,443 | $63.02 | $153,957.86 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 4 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,869 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $63.02 | $25,206.00 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 3 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,312 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 17,686 | $63.01 | $1,114,394.86 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,712 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,570 | $63.01 | $350,937.85 |
DisclosureSEC source: 0001179110-18-001373 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,398 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 49,000 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · derivative · entry 34 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 49,000 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 19,600 | $0.00 Strike: $27.03 | $0.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · derivative · entry 33 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 19,600 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 10,400 | $0.00 Strike: $22.39 | $0.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · derivative · entry 32 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 10,400 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 4,467 | $0.00 Strike: $26.19 | $0.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · derivative · entry 31 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 4,467 shares Expires 2020-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 21,789 | $63.00 | $1,372,707.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 30 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,968 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,303 | $63.00 | $334,062.49 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 29 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,757 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,600 | $62.99 | $226,764.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 28 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,060 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $62.99 | $6,298.75 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 27 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,660 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,346 | $62.99 | $84,777.81 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 26 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,760 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $62.98 | $62,980.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 25 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,106 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $62.98 | $25,190.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 24 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,106 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,000 | $62.97 | $125,940.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 23 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,506 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $62.97 | $12,593.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 22 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,506 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,700 | $62.96 | $169,992.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 21 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,706 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $62.96 | $12,591.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 20 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,406 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,100 | $62.95 | $69,245.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 19 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,606 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $62.93 | $12,586.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 18 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,706 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $62.91 | $12,582.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 17 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,906 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $62.90 | $6,290.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 16 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,106 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $62.90 | $12,579.50 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 15 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,206 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $62.89 | $12,578.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 14 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,406 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $62.88 | $25,152.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 13 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,606 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $62.86 | $6,286.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 12 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,006 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $62.85 | $6,285.00 |
DisclosureSEC source: 0001179110-18-001372 · edgar.xml · nonDerivative · entry 11 Ford Robert B · CIK 0001612571 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,106 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.